Filing Flows › Conmed (CNMD) › Q2 2025
Conmed (CNMD) Q2 2025 earnings results (second quarter 2025)
10-Q filed Jul 31, 2025
Conmed (CNMD) reported revenue of $342M for the second quarter 2025 (Q2 2025), +3% from a year earlier and +7% from the quarter before. Operating margin was 11.1%, net earnings $21.4M (6.3% of revenue).
Conmed, Q2 2025: revenue $342M (+3% year over year), operating margin 11.1%, net earnings $21.4M, operating cash flow $29.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $342M | +7% | +3% |
| Gross profit | $188M | +6% | +2% |
| Operating profit | $38.2M | +139% | -19% |
| Net earnings | $21.4M | +255% | -29% |
| Operating cash flow | $29.1M | -30% | -33% |
| Free cash flow | $23.4M | -38% | -41% |
What changed
Revenue was $342.3M in Q2 2025, up 3% year over year and up 7% from the previous quarter. General Surgery was the largest line at 59% of revenue. General Surgery added $9.1M year over year (up 5%), 88% of the total change.
Gross margin was 55.0%, down 0.3 points from a year earlier. Operating profit was $38.2M, a 11.1% margin (down 3.0 points year over year). Operating profit fell $8.9M even though revenue rose $10.2M versus a year earlier, so costs grew faster than sales. Operating expenses grew 10% against revenue growth of 3%. The fastest-growing cost line was SG&A (+11%). Net earnings were $21.4M, down 29% year over year. The effective tax rate was 28.4%.
Operating cash flow was $29.1M (down 33% year over year), 136% of net earnings. Non-cash charges added back $13.2M of depreciation and amortization and $4.9M of share-based compensation. Working capital and other items used $10.4M. Capital expenditures of $5.7M left free cash flow of $23.4M.
Questions
What was Conmed's revenue in the second quarter 2025?
Conmed (CNMD) reported revenue of $342M for the second quarter 2025 (Q2 2025), +3% from a year earlier and +7% from the quarter before.
Was Conmed profitable in the second quarter 2025?
Operating profit was $38.2M (11.1% of revenue) and net earnings $21.4M.
Source: Conmed 10-Q on SEC EDGAR.